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Abstract
Background: The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate
prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain
unclear in patients with t(8;21) acute myeloid leukemia (AML).
Methods: RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at
scheduled time points after transplantation (1530 samples in total).
Results: A total of 92.3% of the requested samples were collected, and 74.0% of patients had complete sample
collection. The 1-, 3-, and 6-month RUNX1-RUNX1T1 transcript levels could significantly discriminate between continuous
complete remission and a hematologic relapse at 1.5–3, 4–6, and 7–12 months but not at >3, >6, and >12 months,
respectively. Over 90% of the 175 patients who were in continuous complete remission had a ≥3-log reduction in
RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a ≥4-log
reduction at ≥12 months. A <3-log reduction within 12 months and/or a <4-log reduction at ≥12 months was
significantly related to a higher 3-year cumulative incidence of relapse (CIR) rate in both the entire cohort and the
patients with no intervention after HSCT (58.4 vs. 2.2%, 76.5 vs. 2.0%; all P < 0.0001). Patients who had received a
preemptive donor lymphocyte infusion when the increase in RUNX1-RUNX1T1 transcripts was ≤1-log according to the
above dual cutoff values had significantly lower 1-year CIR rate after intervention than the patients who had received an
infusion when the increase was >1-log (0 vs. 55.0%, P = 0.015).
Conclusions: RUNX1-RUNX1T1 transcripts with a <3-log reduction from diagnosis within 12 months and/or a <4-log
reduction at ≥12 months after allo-HSCT could accurately predict relapse and may prompt a timely intervention in
patients with t(8;21) AML.
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Background
Although t(8;21) acute myeloid leukemia (AML) is
considered to have a good prognosis, relapse occurs
in up to 40% of patients treated with chemotherapy
[1–6]. Allogeneic hematopoietic stem cell transplant-
ation (allo-HSCT) is a potentially curative approach
for patients with acute myeloid leukemia (AML) [7–9].
High-risk t(8;21) AML patients benefited from allo-
HSCT in our previously published report [6]. Even
after they had received HSCT, 10–20% of patients still
experienced relapse, which led to a poor long-term
outcome [10, 11].
In patients with t(8;21) AML, the presence of minimal
residual disease (MRD), measured by RUNX1-RUNX1T1
transcript levels, is now established as a powerful marker
to predict relapse and to direct clinical interventions for
patients receiving chemotherapy or transplantation [4–6,
10, 12–16]. Our previous study indicated that a <3-log re-
duction from diagnosis in RUNX1-RUNX1T1 transcripts
at the first 3 months post-HSCT generally identified high
relapse risk patients [12].
Additionally, we realized that patients with an early ≥3-
log reduction in RUNX1-RUNX1T1 transcripts might ex-
perience late relapse post-HSCT. Regarding the prediction
of relapse that occurs at all time points after HSCT, only a
few case reports and studies with a very small sample size
have shown that an increase in the number of RUNX1-
RUNX1T1 transcripts occurred prior to hematologic re-
lapse [16–18]. Due to the low incidence of t(8;21) AML
[19] and its low proportion of patients undergoing allo-
geneic transplantation, no large-scale study results have
been presented to date. As a result, the exact threshold of
MRD levels and monitoring schedules for the accurate
prediction of relapse at all time points after allo-HSCT re-
main unclear.
In the current study, we evaluated the RUNX1-
RUNX1T1 transcript levels in 208 patients who were
monitored at scheduled time points after HSCTand found
that a <3-log reduction from diagnosis within 12 months
and/or a <4-log reduction at ≥12 months accurately pre-
dicted relapse at all time points after HSCT and led to an
effective preemptive donor lymphocyte infusion (DLI).
Methods
Patients, treatment, and samples
A total of 208 t(8;21) AML patients were included in
this study. They were in complete remission (CR, first or
second) at the time of HSCT and consecutively received
allo-HSCT at our institute from March 2006 to May
2016. All patients received induction therapy (one to four
courses) to achieve CR, followed by at least 2 cycles of
consolidation therapy before receiving a transplant. Indi-
cations for allo-HSCT included (1) hematologic relapse,
(2) meeting the high-risk criteria that we published (not
achieving a ≥3-log reduction after the second consolida-
tion and/or the loss of a ≥3-log reduction during the next
six consolidation therapies) [6], (3) c-KIT mutations at the
time of diagnosis [20], and (4) the patient’s repeated re-
quest. The allo-HSCT conditioning regimen, graft-versus-
host disease (GVHD) prophylaxis, modified DLI regimen,
and preemptive interferon-a (IFN-a) treatment for MRD
were performed as previously described [8, 21, 22]. All pa-
tients who received haploidentical, unrelated or cord
blood grafts were administered an oral dose of rabbit anti-
thymocyte globulin (ATG, 2.5 mg/kg; Sanofi, Gentilly,
France) on days five to two before transplantation. A
modified DLI or IFN-a were given before hematological
relapse as intervention therapy after 3 months post-HSCT
following a trial of immunosuppressant withdrawal if pa-
tients did not achieve a ≥3-log reduction of RUNX1-
RUNX1T1 until 3 months or lost a ≥3-log reduction after
HSCT without uncontrolled GVHD or severe infection
according to donor availability and willingness.
The monitoring schedule was planned in advance, and
the scheduled time points were 0, 1, 2, 3, 4.5, 6, 9, 12,
18, and 24 months post-HSCT. Morphologic evaluations
and the quantitative measurement of RUNX1-RUNX1T1
transcripts in bone marrow (BM) samples were performed
at the specified time points and when patients showed
signs of relapse. The cutoff date for follow-up was August
15, 2016. The median follow-up time after HSCT was 24
(2–89) months in the entire cohort. The study was
approved by the Ethics Committee of Peking University
People’s Hospital, and all patients or their guardians pro-
vided written informed consent to participate in the study
in accordance with the Declaration of Helsinki.
Measurement of RUNX1-RUNX1T1 transcript levels
TRIzol reagent (Invitrogen, CA, USA) was used to ex-
tract total RNA. A high capacity cDNA reverse tran-
scription kit (Applied Biosystems, Foster City, CA, USA)
was used to synthesize complementary DNA (cDNA).
TaqMan-based real-time quantitative PCR (RQ-PCR)
technology was used as described previously [6, 7, 17].
The primers and probes for ABL and RUNX1-RUNX1T1
were obtained from the report of the Europe Against
Cancer Program [23, 24]. Quality control samples were in-
cluded in each PCR run. All amplifications were per-
formed at least in duplicate. The RUNX1-RUNX1T1
transcript level was calculated as the percentage of
RUNX1-RUNX1T1 transcript copies/ABL copies. The
pretreatment baseline level of RUNX1-RUNX1T1 tran-
scripts was 400% in our laboratory [6]. The reproducible
sensitivity of RQ-PCR is five copies. All of the samples
with an undetectable fusion transcript had ≥12,500
copies of ABL to guarantee that at least a 4-log re-
duction of RUNX1-RUNX1T1 transcript levels (0.04%)
could be detected.
Qin et al. Journal of Hematology & Oncology  (2017) 10:44 Page 2 of 9
Statistical analysis and definitions
The cumulative incidence of relapse (CIR), disease free
survival (DFS), and overall survival (OS) were measured
from the time of allo-HSCT. Standard definitions of re-
lapse were used. Relapses included BM and/or extra-
medullary sites. The events for measuring DFS included
death and relapse. The event for measuring OS was
death (regardless of the cause), and patients, or their rel-
atives, were queried at the date of last follow-up to de-
termine whether they were still living or censored on the
date that they were last known to be alive. Comparisons
of the CIR between the groups were calculated by con-
sidering the competing risks defined by death and per-
formed with the Gray test. The molecular response (the
log reduction of RUNX1-RUNX1T1 transcript levels)
was considered a time-dependent covariate, i.e., the start
time point of the CIR rate curves according to the tran-
script levels at a specific time point was that specific
time point. Survival functions were estimated using the
Kaplan-Meier method and compared using the log-rank
test. Comparisons between the two groups were per-
formed using the Mann-Whitney U test for continuous
variables and Fisher’s exact test for categorical variables.
Receiver operating characteristic (ROC) curves were
used to evaluate the effect of RUNX1-RUNX1T1 tran-
script levels after HSCT on relapse. The level for a stat-
istical significance was set at P ≤ 0.05. R version 2.6.1 (R
Foundation for Statistical Computing, Vienna, Austria),
SPSS 13.0 (SPSS Inc., Chicago, IL, USA), and GraphPad
Prism 5 (GraphPad Software Inc., La Jolla, CA, USA)
software were used.
Results
Patient characteristics, outcomes, and time of relapse
Patient characteristics at the time of diagnosis and
HSCT are shown in Table 1. After receiving allo-HSCT,
33 (15.9%) patients experienced relapse; 25 and 8 pa-
tients suffered only hematologic and extra-medullary re-
lapse, respectively. A total of 156 (75.0%) patients were
alive at the last follow-up; a total of 22 patients died of
relapse, and 30 died due to treatment-related mortality.
The median follow-up time after allo-HSCT was 26
(3–89) months for the surviving patients. The 3-year
CIR, DFS, and OS rates were 20.4% (95% confidence
interval (CI), 9.9–33.6%), 65.4% (95% CI, 57.4–72.2%),
and 70.8% (95% CI, 62.9–77.3%), respectively.
The median relapse time point was 6 months (range
1.5–43 months) after HSCT for 33 relapsed patients. A
total of 27 (82%) patients experienced relapse within the
first year after HSCT (11 at 1.5–3 months, 6 at 4–
6 months, and 10 at 7–12 months), and the remaining 6
(18%) patients relapsed after 12 months (at 26–43 months
after HSCT).
Sample collection and monitoring implementation
Seventy-four percent (154/208) of patients were col-
lected of all requested samples with qualified ABL cop-
ies. Of the 54 patients with incomplete collections, 30
(55.6%) and 14 (25.9%) lacked 1 and 2 qualified re-
quested samples, respectively. In all, RUNX1-RUNX1T1
transcripts were measured in 1530 BM samples in this
study, which accounted for 92.3% of the requested num-
ber of samples.
A <3-log reduction from diagnosis in RUNX1-RUNX1T1
transcripts within the first 3 months after HSCT predicted
relapse
Patients with a <3-log reduction in RUNX1-RUNX1T1
transcripts at 1–3 months after HSCT had a significantly
higher 3-year CIR rate than those with a ≥3-log reduc-
tion (54.5% [95% CI, 40.3–70.8%]) vs. 11.6% [95% CI,
3.0–31.5%]; P < 0.0001, Fig. 1).
Table 1 Patient characteristics
Parameters n = 208




c-KIT gene at diagnosis
Mutation 69 (33%)
Wild type 80 (39%)
Unknown 59 (28%)




Interval between diagnosis and HSCT
<8 months 110 (53%)
≥8 months 98 (47%)
Disease status when receiving HSCT
First CR 179 (86%)
Second CR 29 (14%)
Donor source
HLA-matched sibling 60 (29%)
Haploidentical 135 (65%)
Unrelated donor 10 (5.5%)
Cord blood 1 (0.5%)
Conditioning regimen
Chemotherapy based 204 (98.1%)
TBI based 4 (1.9%)
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A <3-log reduction in RUNX1-RUNX1T1 transcripts within the
first 3 months was relevant to early but not to late relapse
Figure 1 shows that some of the patients who had
achieved a ≥3-log reduction in RUNX1-RUNX1T1 tran-
scripts at 1–3 months still suffered a relapse. The effect
of the early MRD level on relapse was further analyzed
in terms of relapse time. The distributions of patients
are shown in Fig. 2. A <3-log reduction in RUNX1-
RUNX1T1 transcripts at 1–3 months was significantly
associated with a higher rate of relapse at 1.5–6 months
than a ≥3-log reduction (relapses after 6 months were ex-
cluded. 16/31 vs. 1/161, 51.6 vs. 0.6%, P < 0.0001); a <3-log
reduction in RUNX1-RUNX1T1 transcripts was not re-
lated to relapse after 6 months (relapses at 1.5–6 months
were excluded. 2/17 vs. 14/174, 11.8 vs. 8.0%, P = 0.64).
The RUNX1-RUNX1T1 transcript levels after HSCT only
predicted the forthcoming relapse
ROC curve analysis was performed. To evaluate the ef-
fect of the 1-month RUNX1-RUNX1T1 transcript levels
on relapse, the patients were categorized into three
groups: continuous CR, relapse at 1.5–3 months, and
relapse after 3 months. The analysis demonstrated that
the 1-month RUNX1-RUNX1T1 transcript levels could
significantly discriminate continuous complete remission
(CR) from relapse at 1.5–3 months (area under the curve
[AUC] 0.85, P < 0.0001), but not relapse after 3 months
(AUC 0.53, P = 0.62). Similarly, the 3-month RUNX1-
RUNX1T1 levels significantly discriminated continuous
CR from relapse at 4–6 months (AUC 0.98, P < 0.0001),
but not at >6 months (AUC 0.60, P = 0.24). In addition,
the 6-month RUNX1-RUNX1T1 levels could discriminate
continuous CR from relapse at 7–12 months (AUC 0.75,
P = 0.009), but not after 12 months (AUC 0.50, P = 0.98).
The RUNX1-RUNX1T1 transcript levels at 1, 3, and
6 months were individually compared among the pa-
tients in continuous CR, the patients who had experi-
enced forthcoming relapse, and the patients who had
experienced late relapse. At 1 month, the RUNX1-
RUNX1T1 transcript levels in the patients in continuous
CR were significantly lower than in the patients who had
relapsed at 1.5–3 months, but similar levels to that in
the patients who had relapsed after 3 months (Fig. 3a).
Likewise, at 3 months, the CR patients had significantly
lower RUNX1-RUNX1T1 transcript levels than those who
had relapsed at 4–6 months, but similar levels to those
patients who had relapsed after 6 months (Fig. 3b). At
6 months, the CR patients had significantly lower RUNX1-
RUNX1T1 transcript levels than those who had relapsed at
7–12 months but had levels that were similar to those pa-
tients who had relapsed after 12 months (Fig. 3c).
These results showed that RUNX1-RUNX1T1 tran-
script levels after HSCT only predicted forthcoming re-
lapse but not late relapse. Therefore, serial monitoring
of RUNX1-RUNX1T1 transcripts after HSCT is needed
for the accurate prediction of relapse at any time.
Dynamic patterns of RUNX1-RUNX1T1 transcript levels
after HSCT in patients in continuous CR
As shown in Table 2, for the patients in continuous CR
(n = 175), the RUNX1-RUNX1T1 transcript levels grad-
ually decreased after HSCT, which was demonstrated by
the gradual reduction of the median RUNX1-RUNX1T1
transcript levels and the increase of the percentage of pa-
tients with a ≥3-log and a ≥4-log reduction in RUNX1-
Fig. 1 CIR rates of the patients categorized according to their
RUNX1-RUNX1T1 transcript levels at the first 3 months after HSCT
Fig. 2 Distribution of the patients according to their reduction in RUNX1-RUNX1T1 transcript levels at 1–3 months and relapse time
after allo-HSCT
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RUNX1T1 transcripts. Over 90% of patients had a ≥3-log
reduction from the first month and had a ≥4-log reduction
at ≥12 months post-HSCT. In addition, these two fre-
quencies were similar at each time point starting at
12 months (P > 0.05). Therefore, ≥3-log and ≥4-log reduc-
tions in RUNX1-RUNX1T1 transcripts were individually
chosen as the thresholds for the prediction of relapse
within the first year and starting at 12 months post-HSCT,
respectively.
A <3-log reduction within 12 months and/or a <4-log
reduction at ≥12 months after HSCT predicted relapse at
all time points after allo-HSCT
As shown in Fig. 4, both a <3-log reduction in RUNX1-
RUNX1T1 transcripts within 12 months and a <4-log re-
duction in RUNX1-RUNX1T1 transcripts at ≥12 months
post-HSCT significantly predicted relapse, respectively
(Fig. 4a and b, all P < 0.0001). In addition, patients who
had a ≥3-log reduction in RUNX1-RUNX1T1 transcripts
within 12 months and a ≥4-log reduction at ≥12 months
(defined as low MRD levels after HSCT, n = 151) have
significantly lower 3-year CIR rates than patients with
a <3-log reduction within 12 months and/or a <4-log
reduction at ≥12 months (defined as high MRD levels
after HSCT, n = 57) in the entire cohort (2.2% [95%
CI, 0–30.6%] vs. 58.4% [95% CI, 45.5–68.7%]; P < 0.0001;
Fig. 4c). This result was also observed in the patients
with no intervention after HSCT (n = 144 and 21,
2.0% [95% CI, 0–36.5%] vs. 76.5% [95% CI, 74.9–85.5%];
P < 0.0001; Fig. 4d).
A ≤1-log increase according to the dual thresholds
directed effective preemptive DLI
Of the 43 patients who were given intervention therapy,
24 received preemptive DLI (12 also received IFN-a) for
the prevention of hematologic relapse. The median time
point at which DLI was received was 6 months (range
3–26 months) post-HSCT, and the median RUNX1-
RUNX1T1 transcript level was 3.1% (range 0.12–163.0%)
at the time of the intervention. The patients were cate-
gorized according to their RUNX1-RUNX1T1 transcript
levels at the time of DLI. Nine patients received
Fig. 3 Comparisons of the RUNX1-RUNX1T1 transcript levels at 1, 3, and 6 months among the patients in continuous CR, the patients who had
experienced forthcoming relapse and the patients who had experienced late relapse. a RUNX1-RUNX1T1 transcript levels at 1-month post-HSCT.
b RUNX1-RUNX1T1 transcript levels at 3 months post-HSCT. c RUNX1-RUNX1T1 transcript levels at 6 months post-HSCT












1 174 0.011% (0–12.8%) 163 (93%) 121 (70%) <0.0001
2 167 0.0062% (0–22.5%) 160 (96%) 132 (79%) <0.0001
3 161 0 (0–17.8%) 153 (95%) 127 (79%) <0.0001
4.5 126 0 (0–1.5%) 122 (97%) 93 (74%) <0.0001
6 143 0 (0–2.4%) 139 (97%) 123 (86%) 0.001
9 113 0 (0–4.1%) 111 (98%) 99 (88%) 0.003
12 118 0 (0–0.66%) 116 (98%) 110 (93%) 0.10
18 90 0 (0–0.30%) 90 (100%) 87 (97%) 0.25
24 72 0 (0–0.30%) 72 (100%) 68 (94%) 0.12
30 23 0 (0–0.49%) 22 (96%) 22 (96%) 1.0
36 27 0 (0–0.005%) 27 (100%) 27 (100%) 1.0
*Comparison of the frequency of patients with a ≥3-log reduction with the frequency of patients with a ≥4-log reduction at each time point
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preemptive DLI when their RUNX1-RUNX1T1 tran-
scripts were increased by ≤1-log according to the above
dual thresholds (that is, a 2–3-log reduction from diag-
nosis in RUNX1-RUNX1T1 transcripts within 12 months
[n = 8] or a 3–4-log reduction at ≥12 months [n = 1]),
and 15 patients received preemptive DLI when their in-
crease was >1-log (<2-log reduction within 12 months
[n = 11] or <3-log reduction at ≥12 months [n = 4]).
Figure 5 reveals that the patients in the former group
had significantly lower 1-year CIR rate after intervention
than the patients in the latter group (0 vs. 55.0%
[95% CI, 33.9–68.7%]; P = 0.015). This finding indi-
cates that if the cutoff values for prompting preemp-
tive DLI were increased by 1-log, it could no longer
effectively prevent relapse.
The impact of factors other than the RUNX1-RUNX1T1
transcript levels after HSCT on relapse
As shown in Table 3, mutated c-KIT gene, HLA-
matched sibling donor and <3-log reduction of RUNX1-
RUNX1T1 transcript levels pre-HSCT were significantly
related to a higher 3-year CIR rate (all P < 0.05), and
Fig. 4 Comparisons of the CIR rates among patients with different MRD levels after HSCT. a The patients were grouped according to whether
they achieved a ≥3-log reduction within 12 months. b The patients were grouped according to whether they achieved a ≥4-log reduction at
≥12 months. c All of the patients were grouped according to the dual cutoff values. d The patients with no intervention after HSCT were
grouped according to the dual cutoff values
Fig. 5 CIR rates of the patients grouped by the increase in RUNX1-
RUNX1T1 transcripts compared with the dual thresholds at the time
of preemptive DLI
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second CR status pre-HSCT tended to be significantly
related to a higher 3-year CIR rate (P = 0.071).
The impact of acute GVHD on the evolution of the
RUNX1-RUNX1T1 transcript levels is shown in the
Additional file 1.
Discussion
MRD-directed therapy is a new treatment strategy for
patients with AML who receive chemotherapy as well as
transplantation. Determination of the cutoff MRD value
and the monitoring schedule is the present challenge. In
the current study, we demonstrated that the dynamics of
RUNX1-RUNX1T1 transcript levels accurately predicted
relapse after allo-HSCT in patients with t(8;21) AML.
Furthermore, MRD monitoring results directed the pre-
emptive use of DLI, which effectively decreased the oc-
currence of a hematological relapse.
t(8;21) is a rare disease that accounts for approxi-
mately 8% of AML cases [17]. In addition, because
t(8;21) is defined as a favorable characteristic, only high-
risk patients have been recommended to receive allo-
HSCT in recent years [6]. As a result, all of the studies
concerning MRD in t(8;21) AML patients who received
an allo-HSCT had small sample sizes or were case re-
ports [15–17], except for the study that we published in
2014 [10]. In that paper, we described the effect of
changes in RUNX1-RUNX1T1 transcript levels in the
first 3 months after allo-HSCT on relapse prediction. To
date, no studies have investigated the optimal MRD
thresholds and the monitoring schedules for the predic-
tion of relapse at all time points after allo-HSCT in pa-
tients with t(8;21) AML.
Several studies have individually shown that a 3-log re-
duction in RUNX1-RUNX1T1 transcripts is a meaningful
threshold at distinct time points during chemotherapy
[4–6]. Regarding transplantation, our multicenter data
demonstrated that a ≤3-log reduction at the first
3 months after HSCT was an independent factor for
CIR, which could be used to rapidly identify those at
high risk of relapse [10].
In the present study, we confirmed the predictive
value of a 3-log reduction in RUNX1-RUNX1T1 tran-
scripts in the first 3 months for relapse in the entire co-
hort. However, despite the statistical significance, the
majority of late relapse events could not be predicted by
the MRD status within the first 3 months. Both the ROC
curve analysis and the comparisons of the RUNX1-
RUNX1T1 transcripts showed that 1-, 3, and 6-month
RUNX1-RUNX1T1 transcript levels could significantly
discriminate continuous CR from hematologic relapse
that occurred at 1.5–3, 4–6, and 7–12 months but
not at >3, >6, or >12 months, respectively. This find-
ing suggested that RUNX1-RUNX1T1 transcript levels
after HSCT only predict forthcoming relapse. There-
fore, the serial monitoring of RUNX1-RUNX1T1 tran-
script levels is needed to predict the occurrence of
relapse at all time points after HSCT.
Previous studies have demonstrated that a rapid in-
crease in RUNX1-RUNX1T1 transcripts was typically
found before relapse occurred [13–18]. This finding sug-
gested that the dynamics of RUNX1-RUNX1T1 after
HSCT might predict a relapse. However, the cutoff
values and the monitoring time points needed to be de-
termined. In the current study, these determinations
were made by the analysis of RUNX1-RUNX1T1 dynam-
ics in patients who were maintained in continuous CR
after HSCT. We found that over 90% of patients exhib-
ited a ≥3-log reduction and a ≥4-log reduction in
RUNX1-RUNX1T1 transcripts from the first month and
at ≥12 months, respectively. Furthermore, the presence
of similar frequencies at ≥12 months reflected that these
Table 3 The impact of factors other than the RUNX1-RUNX1T1
transcript levels after HSCT on relapse
Factors 3-year CIR rate (95% CI) P value
WBC count at diagnosis
≤ 10 × 109/L 24.6% (9.1–44.0%) 0.31
> 10 × 109/L 17.1% (5.1–35.0%)
c-KIT gene
Mutation 38.4% (20.0–56.6%) 0.003
Wild type 15.4% (2.4–38.9%)
Karyotype
Sole t(8;21) 20.6% (4.3–45.4%) 0.56
Additional abnormalities 21.6% (7.6–40.3%)
Course acquired to achieve CR
1 19.0% (6.1–372%) 0.20
> 1 24.2% (7.9–45.3%)
Time interval from diagnosis to transplant
< 8 months 23.5% (9.4–41.2%) 0.87
≥ 8 months 16.4% (4.3–35.5%)
Disease status pre-HSCT
1st CR 18.8% (7.7–33.6%) 0.071
2nd CR 33.3% (9.0–60.4%)
Donor resource
HLA-matched sibling 31.4% (13.5–51.2%) 0.039
Alternative donor 14.6% (4.2–31.0%)
RUNX1-RUNX1T1 transcript levels pre-HSCT
≥ 3-log reduction 11.1% (0.9–36.4%) <0.0001
< 3-log reduction 27.9% (14.6–42.9%)
Acute GVHD
With 21.6% (7.5–40.5%) 0.52
Without 18.9% (6.0–37.3%)
Statistically significant factors are italicized
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two cutoff values categorized similar amounts of patients
into the continuous CR group. Because the cutoff value
selection criteria were designed to categorize the highest
number of poor-outcome patients into the high-risk
group, we developed dual cutoff values: a 3-log reduc-
tion for the first year and a 4-log reduction thereafter.
As expected, these values accurately predicted relapse in
the entire cohort as well as in patients who had received
no intervention.
Our previous paper demonstrated that interventions
with preemptive DLI decreased the rate of post-HSCT
relapse in patients with t(8;21) AML [10]. However, the
threshold of RUNX1-RUNX1T1 transcripts for the imple-
mentation of an effective intervention remains unclear. In
this study, we found that the CIR rate of patients who re-
ceived DLI when their RUNX1-RUNX1T1 transcripts
were within a 1-log increase from the dual thresholds was
significantly lower than that of patients receiving DLI at
the time of a >1-log increase. Therefore, the effectiveness
of preemptive DLI is relevant to RUNX1-RUNX1T1 tran-
script level at the time of the intervention. A DLI could
not prevent hematologic relapse once the leukemic bur-
den was too high. The results demonstrated that the dual
cutoff values that we established may direct a timely and
effective intervention. However, this result must be con-
firmed in more cases.
Apart from the RUNX1-RUNX1T1 transcript levels
after HSCT, c-KIT mutation status, donor type, and
RUNX1-RUNX1T1 transcript levels pre-HSCT were also
found to be related to relapse after HSCT in the current
cohort. Previous studies have shown the prognostic value
of these factors in AML. The c-KIT mutation is a strong
poor prognostic factor in t(8;21) AML [6, 10, 20, 25].
MRD levels before allogeneic HSCT have been demon-
strated to be associated with adverse outcomes in AML by
many studies [26, 27]. We previously reported that high-
risk acute leukemia patients receiving haploidentical
donor grafts had a significantly lower relapse rate than
those receiving HLA-identical sibling donor grafts [28].
The monitoring schedule of this study was planned in
advance. In patients who had received allo-HSCT, re-
lapse mostly occurred within the first year, and the re-
lapse rate was highest within the first 3 months; the time
interval was therefore set at 1 month within the first
3 months and gradually increased thereafter. A recent
report on prospective monitoring in t(8;21) AML pa-
tients showed that 71.3% of BM samples that were
planned by the protocol were collected [14]. In the
present study, 92.3% of the planed samples were col-
lected, and 74.0% of the patients followed the sched-
ule. This finding implied that the results of the
current study could represent the effect of this moni-
toring schedule, and such scheduled monitoring ef-
fectively predicted relapse.
Conclusions
The results of the present study indicate that monitoring
the dynamics of RUNX1-RUNX1T1 transcripts could pre-
dict relapse at all time points after allo-HSCT in patients
with t(8;21) AML. A <3-log reduction and a <4-log reduc-
tion from diagnosis in RUNX1-RUNX1T1 transcripts
within 12 months and at ≥12 months post-HSCT, respect-
ively, were the optimal thresholds to predict relapse. A <1-
log increase relative to the above dual thresholds directed
the timely and effective use of preemptive DLI. These re-
sults should be confirmed in a multi-center study.
Additional file
Additional file 1: Impact of acute GVHD on the evolution of RUNX1-
RUNX1T1 transcript levels. (DOCX 15 kb)
Abbreviations
allo-HSCT: Allogeneic hematopoietic stem cell transplantation; AML: Acute myeloid
leukemia; AUC: Area under the curve; CI: Confidence interval; CIR: Cumulative
incidence of relapse; DFS: Disease-free survival; DLI: Donor lymphocyte infusion;
GVHD: Graft-versus-host disease; IFN-a: Interferon-a; MRD: Minimal residual disease;
OS: Overall survival; RQ-PCR: Real-time quantitative PCR
Acknowledgements
The authors thank all of the doctors at the institute who participated in this
study for providing the follow-up samples and information.
Funding
This work was supported by the Foundation for Innovative Research Groups
of the National Natural Science Foundation of China (81621001), the National
Nature Science Foundation of China (81570130, 81530046), and the Beijing
Municipal Science and Technology Program (Z141100000214011).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
XJH designed the research and revised the paper. YZQ and YW analyzed the
data and wrote the paper. LPX, XHZ, HC, WH, YHC, FRW, JZW, YC, XDM, XSZ,
YJC, and KYL collected and analyzed data. All authors read and approved the
final manuscript and submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable for individual patient data. This is a pooled analysis.
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Peking University
People’s Hospital, and all patients or their guardians provided written
informed consent to participate in the study in accordance with the
Declaration of Helsinki.
Received: 24 October 2016 Accepted: 1 February 2017
References
1. Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, et al.
Individual patient data-based meta-analysis of patients aged 16 to 60 years
with core binding factor acute myeloid leukemia: a survey of the German
Acute Myeloid Leukemia InterGroup. J Clin Oncol. 2004;22:3741–50.
2. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al.
Prognostic factors and outcome of core binding factor acute myeloid
Qin et al. Journal of Hematology & Oncology  (2017) 10:44 Page 8 of 9
leukemia patients with t(8;21) differ from those of patients with inv(16): a
Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–17.
3. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT,
et al. The clinical spectrum of adult acute myeloid leukaemia associated
with core binding factor translocations. Br J Haematol. 2006;135:165–73.
4. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal
residual disease monitoring by quantitative RT-PCR in core binding factor
AML allows risk stratification and predicts relapse: results of the United
Kingdom MRC AML-15 trial. Blood. 2012;120:2826–35.
5. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al.
Prospective evaluation of gene mutations and minimal residual disease
in patients with core binding factor acute myeloid leukemia. Blood.
2013;121:2213–23.
6. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRD-directed
risk stratification treatment may improve outcomes of t(8;21) AML in the
first complete remission: results from the AML05 multicenter trial. Blood.
2013;121:4056–62.
7. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen
SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of
myeloablative HLA-identical sibling stem cell transplantation in first
remission acute myeloid leukemia in young and middle-aged adults:
benefits for whom? Blood. 2007;109:3658–66.
8. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including
antithymocyte globulin followed by unmanipulated HLA-mismatched/
haploidentical blood and marrow transplantation can achieve comparable
outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.
9. Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, et al. Long-
term survival and late events after allogeneic stem cell transplantation from
HLA-matched siblings for acute myeloid leukemia with myeloablative
compared to reduced-intensity conditioning: a report on behalf of the
acute leukemia working party of European group for blood and marrow
transplantation. J Hematol Oncol. 2016;9:118.
10. Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, et al. In adults with t(8;21)AML,
posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT
mutations, allows further risk stratification. Blood. 2014;124:1880–6.
11. Yoon JH, Kim HJ, Kim JW, Jeon YW, Shin SH, Lee SE, et al. Identification of
molecular and cytogenetic risk factors for unfavorable core-binding factor-
positive adult AML with post-remission treatment outcome analysis
including transplantation. Bone Marrow Transplant. 2014;49:1466–74.
12. Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of
molecular response to chemotherapy is predictive for the outcome of
AML1-ETO-positive AML and is independent of pretreatment risk factors.
Leukemia. 2007;21:1177–82.
13. Leroy H, de Botton S, Grardel-Duflos N, Darre S, Leleu X, Roumier C, et al.
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
Leukemia. 2005;19:367–72.
14. Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze
R, et al. Prospective long-term minimal residual disease monitoring using
RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the
French CBF-2006 trial. Haematologica. 2016;101:328–35.
15. Lane S, Saal R, Mollee P, Jones M, Grigg A, Taylor K, et al. A > or = 1 log rise
in RQ-PCR transcript levels defines molecular relapse in core binding factor
acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk
Lymphoma. 2008;49:517–23.
16. Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA, et al.
Molecular quantitation of minimal residual disease in acute myeloid leukemia
with t(8;21) can identify patients in durable remission and predict clinical
relapse. Blood. 2000;95:815–9.
17. Sugimoto T, Das H, Imoto S, Murayama T, Gomyo H, Chakraborty S, et al.
Quantitation of minimal residual disease in t(8;21)-positive acute
myelogenous leukemia patients using real-time quantitative RT-PCR. Am J
Hematol. 2000;64:101–6.
18. Mitterbauer M, Mitterbauer-Hohendanner G, Sperr WR, Kalhs P, Greinix HT,
Fonatsch C, et al. Molecular disease eradication is a prerequisite for long-
term remission in patients with t(8;21) positive acute myeloid leukemia: a
single center study. Leuk Lymphoma. 2004;45:971–7.
19. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al.
The importance of diagnostic cytogenetics on outcome in AML: analysis of
1,612 patients entered into the MRC AML 10 trial. The Medical Research Council
Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.
20. Qin YZ, Zhu HH, Jiang Q, Jiang H, Zhang LP, Xu LP, et al. Prevalence and
prognostic significance of c-KIT mutations in core binding factor acute
myeloid leukemia: a comprehensive large-scale study from a single Chinese
center. Leuk Res. 2014;38:1435–40.
21. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-
directed donor lymphocyte infusion could reduce relapse of standard-risk
acute leukemia patients after allogeneic hematopoietic stem cell
transplantation. Blood. 2012;119:3256–62.
22. Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Interferon-α: a
potentially effective treatment for minimal residual disease in acute
leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem
cell transplantation. Biol Blood Marrow Transplant. 2015;21:1939–47.
23. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E,
et al. Evaluation of candidate control genes for diagnosis and residual
disease detection in leukemic patients using ‘real-time’ quantitative reverse-
transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer
program. Leukemia. 2003;17:2474–86.
24. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N,
et al. Standardization and quality control studies of ‘real-time’ quantitative
reverse transcriptase polymerase chain reaction of fusion gene transcripts
for residual disease detection in leukemia—a Europe Against Cancer
program. Leukemia. 2003;17:2318–57.
25. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al.
Adverse prognostic significance of KIT mutations in adult acute myeloid
leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J
Clin Oncol. 2006;24:3904–11.
26. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al.
Significance of minimal residual disease before myeloablative allogeneic
hematopoietic cell transplantation for AML in first and second complete
remission. Blood. 2013;122:1813–21.
27. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic
hematopoietic cell transplantation for acute myeloid leukemia: time to
move toward a minimal residual disease-based definition of complete
remission? J Clin Oncol. 2016;34:329–36.
28. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, et al. Superior graft-versus-
leukemia effect associated with transplantation of haploidentical compared
with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic
comparison. Biol Blood Marrow Transplant. 2011;17:821–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Qin et al. Journal of Hematology & Oncology  (2017) 10:44 Page 9 of 9
